The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma

Journal of the National Cancer Institute

Volumn 103, Issue 22, 2011, Pages 1696-1712

  Ai, Jing ^a   Tang, Qingjuan ^b   Wu, Yanlin ^b   Xu, Yang ^c   Feng, Teng ^b   Zhou, Ruiyu ^b   Chen, Yi ^a   Gao, Xin ^a   Zhu, Qingfeng ^c   Yue, Xihua ^a   Pan, Qiuming ^a   Xu, Siyun ^b   Li, Jing ^b   Huang, Min ^a   Daugherty Holtrop, Jennifer ^a,d   He, Yuanzheng ^d   Xu, H Eric ^a,d   Fan, Jia ^c   Ding, Jian ^a   Geng, Meiyu ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b OCEAN UNIVERSITY OF CHINA   (China)

^c FUDAN UNIVERSITY   (China)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 4; PROTEIN TWIST1; PROTEIN TWIST2; REPRESSOR PROTEIN; SECRETORY COMPONENT; SERINE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZEB1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CANCER MODEL; CANCER RECURRENCE; CANCER SURVIVAL; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; EARLY CANCER; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; CADHERINS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CHINA; COLONIC NEOPLASMS; CYTOKINES; DISEASE-FREE SURVIVAL; DOGS; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B, CHRONIC; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, SCID; MICROARRAY ANALYSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, EXPERIMENTAL; PLASMIDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, POLYMERIC IMMUNOGLOBULIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMAD PROTEINS; TIME FACTORS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 81855166106     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr360     Document Type: Article

References (65)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):448-458.
2. Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res. 2010;16(2):390-397.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
4. El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134(6):1752-1763. (Pubitemid 351615415)
5. Fan ST. Selection of HCC patients for liver transplantation: the Milan criteria, Hangzhou criteria and beyond. Hepatobiliary Pancreat Dis Int. 2008;7(3):233-234. (Pubitemid 351895381)
6. De Giorgio M, Fagiuoli S. Management of hepatocellular carcinoma. Dig Dis. 2007;25(3):279-281. (Pubitemid 350194185)
7. Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 2007;72(suppl 1):2-15. (Pubitemid 350256660)
8. Cheung ST, Cheung PF, Cheng CK, et al. Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology. 2011;140(1):344-355.
9. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655-1669. (Pubitemid 351615417)
10. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871-890.
11. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-715. (Pubitemid 351636299)
12. Ansieau S, Bastid J, Doreau A, et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell. 2008;14(1):79-89. (Pubitemid 351890463)
13. Kudo-Saito C, Shirako H, Takeuchi T, et al. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009;15(3):195-206.
14. Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2009;1(6-7):303-314.
15. van Zijl F, Zulehner G, Petz M, et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol. 2009;5(8):1169-1179.
16. Denning GM. IL-4 and IFN-gamma synergistically increase total polymeric IgA receptor levels in human intestinal epithelial cells. Role of protein tyrosine kinases. J Immunol. 1996;156(12):4807-4814. (Pubitemid 26174466)
17. Kvale D, Lovhaug D, Sollid LM, et al. Tumor necrosis factor-alpha up-regulates expression of secretory component, the epithelial receptor for polymeric Ig. J Immunol. 1988;140(9):3086-3089.
18. Rojas R, Apodaca G. Immunoglobulin transport across polarized epithelial cells. Nat Rev Mol Cell Biol. 2002;3(12):944-955. (Pubitemid 35477372)
19. Kaetzel CS. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev. 2005;206(1):83-99. (Pubitemid 41105164)
20. Poger ME, Hirsch BR, Lamm ME. Synthesis of secretory component by colonic neoplasms. Am J Pathol. 1976;82(2):327-338.
21. Harris JP, South MA. Secretory component: a glandular epithelial cell marker. Am J Pathol. 1981;105(1):47-53. (Pubitemid 11018493)
22. Harris JP, Caleb MH, South MA. Secretory component in human mammary carcinoma. Cancer Res. 1975;35(7):1861-1864.
23. Rossel M, Seilles E, Voigt JJ, et al. Polymeric Ig receptor expression in hepatocellular carcinoma. Eur J Cancer. 1992;28A(6-7):1120-1124.
24. Kvale D, Norstein J, Meling GI, et al. Circulating secretory component in relation to early diagnosis and treatment of liver metastasis from colorectal carcinomas. J Clin Pathol. 1992;45(7):568-571.
25. Yang XR, Xu Y, Shi GM, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res. 2008;14(12):3850-3859.
26. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586-2593. (Pubitemid 47041232)
27. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462-503.
28. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. The Liver and Portal Hypertension. Philadelphia, PA: Saunders; 1964:50-64.
29. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
30. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359(19):1995-2004.
31. Poon RT. Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol. 2009;16(4):792-794.
32. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243(2):229-235. (Pubitemid 43185442)
33. Sherman M. Recurrence of hepatocellular carcinoma. N Engl J Med. 2008;359(19):2045-2047.
34. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698-711.
35. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4):262-272. (Pubitemid 43264710)
36. Davidson B, Trope CG, Wang TL, et al. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol. 2006;103(3):814-819. (Pubitemid 44821313)
37. Zhou H, Wang H, Zhou D, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. Eur J Cancer. 2010;46(6):1056-1061.
38. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168-174.
39. Wu Y, Deng J, Rychahou PG, et al. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009;15(5):416-428.
40. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818-829. (Pubitemid 351757205)
41. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429-1437.
42. Mekkawy AH, Morris DL, Pourgholami MH. Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol. 2009;5(9):1487-1499.
43. Dass K, Ahmad A, Azmi AS, et al. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008;34(2):122-136.
44. Johansen FE, Brandtzaeg P. Transcriptional regulation of the mucosal IgA system. Trends Immunol. 2004;25(3):150-157. (Pubitemid 38249489)
45. Bates RC, Mercurio AM. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell. 2003;14(5):1790-1800. (Pubitemid 36583533)
46. Massague J. TGFbeta in Cancer. Cell. 2008;134(2):215-230.
47. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265-273.
48. Takahashi E. Tumor necrosis factor-a regulates transforming growth factor-b-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem. 2010;285(6):4060-4073.
49. Di Guglielmo GM, Le Roy C, Goodfellow AF, et al. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol. 2003;5(5):410-421. (Pubitemid 36592263)
50. Hayes S, Chawla A, Corvera S. TGF beta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. J Cell Biol. 2002;158(7):1239-1249.
51. Hu Y, Chuang JZ, Xu K, et al. SARA, a FYVE domain protein, affects Rab5-mediated endocytosis. J Cell Sci. 2002;115(pt 24):4755-4763. (Pubitemid 36067290)
52. Leung SM, Ruiz WG, Apodaca G. Sorting of membrane and fluid at the apical pole of polarized Madin-Darby canine kidney cells. Mol Biol Cell. 2000;11(6):2131-2150. (Pubitemid 30408069)
53. Okamoto CT, Shia SP, Bird C, et al. The cytoplasmic domain of the polymeric immunoglobulin receptor contains two internalization signals that are distinct from its basolateral sorting signal. J Biol Chem. 1992;267(14):9925- 9932.
54. Casanova JE, Breitfeld PP, Ross SA, et al. Phosphorylation of the polymeric immunoglobulin receptor required for its efficient transcytosis. Science. 1990;248(4956):742-745.
55. Okamoto CT, Song W, Bomsel M, et al. Rapid internalization of the polymeric immunoglobulin receptor requires phosphorylated serine 726. J Biol Chem. 1994;269(22):15676-15682. (Pubitemid 24202160)
56. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-2576. (Pubitemid 46890874)
57. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
58. Traicoff JL, De Marchis L, Ginsburg BL, et al. Characterization of the human polymeric immunoglobulin receptor (PIGR) 3'UTR and differential expression of PIGR mRNA during colon tumorigenesis. J Biomed Sci. 2003;10(6 pt 2):792-804. (Pubitemid 38032496)
59. Koretz K, Schlag P, Quentmeier A, et al. Evaluation of the secretory component as a prognostic variable in colorectal carcinoma. Int J Cancer. 1994;57(3):365-370. (Pubitemid 24168611)
60. Kawai T, Torikata C, Suzuki M. Immunohistochemical study of pulmonary adenocarcinoma. Am J Clin Pathol. 1988;89(4):455-462.
61. Isaacson P. Immunoperoxidase study of the secretory immunoglobulin system in colonic neoplasia. J Clin Pathol. 1982;35(1):14-25. (Pubitemid 12180845)
62. Kondi-Paphitis A, Addis BJ. Secretory component in pulmonary adenocarcinoma and mesothelioma. Histopathology. 1986;10(12):1279-1287. (Pubitemid 17219490)
63. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009;119(6):1417-1419.
64. Lu J, Guo H, Treekitkarnmongkol W, et al. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell. 2009;16(3):195-207.
65. Husemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13(1):58-68. (Pubitemid 350309740)